Summary
A substantial number of patients with Hodgkin's disease (HD) do not respond adequately to standard therapy. Patients who relapse later than 1 year after completion of treatment have a good chance of achieving a second complete remission (CR). The prognosis of patients with primary refractory HD or relapse within 1 year, however, is poor. The long-term results of autologous bone marrow transplantation (ABMT) in these patients have not yet been established. Therefore, we conducted a phase-II study among 15 patients with primary refractory or early relapsed HD, in which they were treated with a two-drug sequential regimen not cross-resistant with MOPP. The patients received two to six courses of methotrexate, cyclophosphamide, adriamycin, vinblastine, CCNU, etoposide, and chlorambucil (M-CAVe-CEC). Seven patients (47%) achieved a CR, including a patient with additional radiotherapy. Actuarial overall survival was 58 and 41%, respectively, and failure-free survival 38% at 2 and 5 years. Gastrointestinal toxicity was acceptable. Dose reductions were necessary in up to 60% of courses given. These preliminary results suggest that the M-CAVe-CEC regimen may be a more effective salvage regimen as compared with other regimens for primary refractory or early relapsed HD. Larger studies, possibly with hematopoietic growth factors, are required to determine its value in comparison to ABMT.
Similar content being viewed by others
References
Armitage JO (1992) Autologous bone marrow transplantation for Hodgkin's disease. Ann Oncol 3 [Suppl 4]: S95-S96
Canellos GP (Editorial) (1992) The second chance for advanced Hodgkin's disease. J Clin Oncol 10:175–176
Desch CE, Lasala MR, Smith TJ, Hillner BE (1992) The optimal timing of autologous bone marrow transplantation in Hodgkin's disease patients after a chemotherapy relapse. J Clin Oncol 10:200–209
DeVita VT, Simon RM, Hubbard SM et al (1980) Curability of advanced Hodgkin's disease with chemotherapy: long-term follow-up of MOPP-treated patients at the National Cancer Institute. Ann Intern Med 92:587–595
DeVita VT, Hellman S, Jaffe ES (1993) Hodgkin's disease. In: De Vita VT, Hellman S, Rosenberg S (eds) Cancer: principles and practice of oncology. 3Lippincott, Philadelphia, pp 1819–1858
Fisher RI, DeVita VT, Hubbard SM et al (1979) Prolonged disease-free survival in Hodgkin's disease with MOPP reinduction after first relapse. Ann Intern Med 90:761–763
Harker WG, Kushlan P, Rosenberg SA (1984) Combination chemotherapy for advanced Hodgkin's disease after failure of MOPP: ABVD and B-CAVe. Ann Intern Med 101:440–446
Hausen HH, Selawry OGS, Pajak TF et al (1981) The superiority of CCNU in the treatment of advanced Hodgkin's disease. Cancer 47:14–18
Longo DL, Duffy PL, Young RC et al (1992) Conventional dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: the low probability for cure. J Clin Oncol 10:210–218
McMillan A, Goldstone A (1991) What is the value of autologous bone marrow transplantation in the treatment of relapsed or resistant Hodgkin's disease? Leukemia Res 15:237–243
Oza AM, Ganesan TS, Leahy M et al (1993) Patterns of survival in patients with Hodgkin's disease: long follow-up in a single centre. Ann Oncol 4:385–392
Santoro A, Bonfante V, Bonadonna GK (1982) Salvage chemotherapy with ABVD in MOPP-resistant Hodgkin's disease. Ann Intern Med 96:139–143
Urba WJ, Longo DL (1992) Hodgkin's disease. N Engl J Med 326:678–687
Viviani S, Santoro A, Negretti E, Bonfante V, Valagussa P, Bonadonna G (1990) Hodgkin's disease: results in patients relapsing more than 12 months after first complete remission. Ann Oncol 1:123–127
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Vreugdenhil, G., Jongen-Lavrencic, M., Raemaekers, J.M.M. et al. Phase-II trial with M-CAVe-CEC as a salvage chemotherapeutic regimen for early relapsed or primary refractory Hodgkin's disease. Ann Hematol 69, 303–306 (1994). https://doi.org/10.1007/BF01696559
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01696559